Form 4: Zimmer Biomet Director Accrues Additional Phantom Stock Units Under Deferred Compensation Plan

Zimmer Biomet Holdings, Inc. Director Devdatt Kurdikar has accrued an additional 150.916 phantom stock units under the company's deferred compensation plan, increasing his total beneficial ownership to 1,470.296 units.

Summary

• Devdatt Kurdikar, a Director at Zimmer Biomet Holdings, Inc. (ZBH), acquired 150.916 phantom stock units.
• The transaction occurred on June 30, 2025.
• These units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
• Each phantom stock unit converts to one share of common stock on a 1-for-1 basis.
• Following this acquisition, Kurdikar beneficially owns a total of 1,470.296 phantom stock units.
• The units are to be settled in shares of company common stock within sixty days after cessation of his service as a Director.

Sentiment

Score: 7

Explanation: The filing indicates a routine, positive event of a director accruing additional equity compensation, aligning interests with shareholders. It does not contain any negative news or significant financial shifts, hence a moderately positive score.

Positives

• Increased alignment of a director's interests with shareholders through additional equity-based compensation.
• Participation in a deferred compensation plan indicates a long-term commitment to the company by the director.

Future Outlook

The phantom stock units are scheduled to be settled in shares of Zimmer Biomet Holdings, Inc. common stock within sixty days after Devdatt Kurdikar ceases his service as a Director.

Industry Context

This Form 4 filing reflects a standard practice in corporate governance where non-employee directors receive equity-based compensation, such as phantom stock units, as part of their remuneration. This aligns their interests with long-term shareholder value, a common trend across the medical device and healthcare industry.

Comparison to Industry Standards

• Equity-based compensation for non-employee directors, including phantom stock units, is a common practice across publicly traded companies, particularly in the healthcare and medical device sectors, aligning director incentives with shareholder returns.
• The use of deferred compensation plans for directors is a standard mechanism to defer income and potentially align long-term interests, consistent with practices observed in companies like Stryker Corporation (SYK) or Medtronic plc (MDT).

Corporate Governance

Stakeholder Impact

• Shareholders: Increased alignment of director's interests with shareholder value through equity-based compensation.

Next Steps

• Settlement of phantom stock units into common stock shares within sixty days after Devdatt Kurdikar's cessation of service as a Director.

Key Dates

Keywords

Zimmer Biomet Holdings, ZBH, Devdatt Kurdikar, Form 4, SEC filing, phantom stock units, deferred compensation, director compensation, equity compensation